Should I buy or sell Applied DNA Sciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Applied DNA Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" APDN shares. View APDN analyst ratings or view top-rated stocks .

What is Applied DNA Sciences' stock price target for 2024?

1 brokers have issued 12-month target prices for Applied DNA Sciences' stock. Their APDN share price targets range from $2.00 to $3.00. On average, they anticipate the company's share price to reach $2.50 in the next year. This suggests a possible upside of 183.8% from the stock's current price. View analysts price targets for APDN or view top-rated stocks among Wall Street analysts .

How have APDN shares performed in 2023?

Applied DNA Sciences' stock was trading at $1.66 at the start of the year. Since then, APDN stock has decreased by 46.9% and is now trading at $0.8810. View the best growth stocks for 2023 here .

When is Applied DNA Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024. View our APDN earnings forecast .

How were Applied DNA Sciences' earnings last quarter?

Applied DNA Sciences, Inc. (NASDAQ:APDN) posted its quarterly earnings data on Thursday, December, 7th. The technology company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.01. The technology company had revenue of $0.78 million for the quarter, compared to analyst estimates of $1.60 million. Applied DNA Sciences had a negative net margin of 74.41% and a negative trailing twelve-month return on equity of 126.68%.

What is James A. Hayward's approval rating as Applied DNA Sciences' CEO?

2 employees have rated Applied DNA Sciences Chief Executive Officer James A. Hayward on Glassdoor.com . James A. Hayward has an approval rating of 100% among the company's employees. This puts James A. Hayward in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Applied DNA Sciences to a friend.

What other stocks do shareholders of Applied DNA Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied DNA Sciences investors own include Inovio Pharmaceuticals (INO) , Advanced Micro Devices (AMD) , Ekso Bionics (EKSO) , Micron Technology (MU) , Arbutus Biopharma (ABUS) , VBI Vaccines (VBIV) , Gilead Sciences (GILD) , Vaxart (VXRT) , Sorrento Therapeutics (SRNE) and Intel (INTC) .

Who are Applied DNA Sciences' major shareholders?

Applied DNA Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include AMH Equity Ltd (4.30%), Sabby Management LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends .

How do I buy shares of Applied DNA Sciences?

Shares of APDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Applied DNA Sciences Stock Price, News & Analysis (NASDAQ:APDN)

$0.88

-0.20 (-18.50%)

(As of 12/8/2023 ET)

Compare

Today's Range: $0.88
▼
$1.00
50-Day Range: $0.75
▼
$1.14
52-Week Range: $0.75
▼
$1.93

Volume: 158,899 shs
Average Volume: 28,252 shs
Market Capitalization: $12.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.50

Applied DNA Sciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 183.8% Upside
$2.50 Price Target
Short Interest: Healthy
2.30% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.21
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Industrial Products Sector

111th out of 176 stocks

Miscellaneous Business Services Industry

3rd out of 6 stocks

3.5

Analyst's Opinion

Consensus Rating
Applied DNA Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.50, Applied DNA Sciences has a forecasted upside of 183.8% from its current price of $0.88.
Amount of Analyst Coverage
Applied DNA Sciences has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.30% of the outstanding shares of Applied DNA Sciences have been sold short.
Short Interest Ratio / Days to Cover
Applied DNA Sciences has a short interest ratio ("days to cover") of 9.5.
Change versus previous month
Short interest in Applied DNA Sciences has recently decreased by 3.69%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Applied DNA Sciences does not currently pay a dividend.
Dividend Growth
Applied DNA Sciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for APDN.

2.3

News and Social Media Coverage

News Sentiment
Applied DNA Sciences has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Industrial Products companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Applied DNA Sciences this week, compared to 1 article on an average week.
Search Interest
3 people have searched for APDN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Applied DNA Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.83% of the stock of Applied DNA Sciences is held by insiders.
Percentage Held by Institutions
Only 17.34% of the stock of Applied DNA Sciences is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Applied DNA Sciences is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Applied DNA Sciences is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Applied DNA Sciences has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Applied DNA Sciences Stock (NASDAQ:APDN)

Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. The company operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR)-based MDx testing services for the Monkeypox virus; and MDx test kits and related supplies, as well as validates pharmacogenetics (PGx) testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, leather, pharmaceuticals, nutraceuticals, and other products; SigNify IF portable DNA readers and SigNify consumable reagent test kits, which offers a front-line solution for supply chain integrity backed with forensic-level molecular tag authentication; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

APDN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

APDN Stock News Headlines

December 9, 2023 | americanbankingnews.com

Applied DNA Sciences (NASDAQ:APDN) Given New $2.00 Price Target at HC Wainwright

December 8, 2023 | benzinga.com

Applied DNA Sciences Stock (NASDAQ:APDN), Quotes and News Summary

December 9, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

December 7, 2023 | finance.yahoo.com

Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results

December 7, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on Applied DNA Sciences (NASDAQ:APDN)

December 5, 2023 | finance.yahoo.com

Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023

November 29, 2023 | americanbankingnews.com

Applied DNA Sciences (NASDAQ:APDN) Coverage Initiated by Analysts at StockNews.com

November 28, 2023 | finance.yahoo.com

Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application

December 9, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 16, 2023 | finance.yahoo.com

Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA)

November 9, 2023 | finance.yahoo.com

Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform

November 5, 2023 | morningstar.com

Applied DNA Sciences Inc APDN

September 14, 2023 | finance.yahoo.com

Applied DNA Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals

September 6, 2023 | finance.yahoo.com

Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs

September 6, 2023 | finance.yahoo.com

Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs

August 29, 2023 | finanznachrichten.de

Applied DNA Sciences, Inc.: Applied DNA Announces Availability and First Customer Shipment of New Linea IVT Evaluation Kit

August 29, 2023 | finance.yahoo.com

Applied DNA Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit

August 24, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Technology Stocks: Autodesk (ADSK), Applied DNA Sciences (APDN)

August 23, 2023 | finance.yahoo.com

Applied DNA Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production

August 11, 2023 | finanznachrichten.de

Applied DNA Sciences, Inc.: Applied DNA Reports Third Quarter Fiscal 2023 Financial Results and Provides Corporate Update

August 11, 2023 | finance.yahoo.com

Applied DNA Reports Third Quarter Fiscal 2023 Financial Results and Provides Corporate Update

August 9, 2023 | benzinga.com

Earnings Preview: Applied DNA Sciences

August 8, 2023 | finance.yahoo.com

ADT (ADT) Q2 Earnings and Revenues Miss Estimates

August 7, 2023 | finance.yahoo.com

Applied DNA to Report Third Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, August 10, 2023

August 4, 2023 | finance.yahoo.com

3 Penny Stocks to Buy Before the Breakout

July 18, 2023 | finanznachrichten.de

Applied DNA Sciences, Inc.: Applied DNA Biotherapeutics Subsidiary LineaRx to Participate in Upcoming mRNA Industry Conferences

July 14, 2023 | markets.businessinsider.com

Analysts Offer Insights on Technology Companies: Applied DNA Sciences (APDN) and Mogo Finance Technology (MOGO)

See More Headlines

Receive APDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied DNA Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 12/07/2023
Today: 12/09/2023
Next Earnings (Estimated): 2/08/2024
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Miscellaneous business services
Sub-Industry: N/A
Sector: Industrial Products
Current Symbol: NASDAQ:APDN
CUSIP: N/A
CIK: 744452
Web: www.adnas.com
Phone: (631) 240-8800
Fax: 631-240-8900
Employees: 61
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.50
High Stock Price Target: $3.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +183.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.75)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,270,000.00
Net Margins: -74.41%
Pretax Margin: -43.79%
Return on Equity: -126.68%
Return on Assets: -60.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.23
Quick Ratio: 4.14

Sales & Book Value

Annual Sales: $13.37 million
Price / Sales: 0.90
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.08 per share
Price / Book: 0.82

Miscellaneous

Outstanding Shares: 13,660,000
Free Float: 12,726,000
Market Cap: $12.03 million
Optionable: Optionable
Beta: 0.63

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. James A. Hayward Ph.D. (Age 69)
Sc.D., Chairman, President & CEO
Comp: $1.27M
Ms. Beth M. Jantzen CPA (Age 47)
Chief Financial Officer
Comp: $390k
Ms. Judith Murrah (Age 65)
COO, Chief Information Officer & Secretary
Comp: $438.75k
Mr. Sanjay M. Hurry
Executive Director of Investor Relations & Corporate Communications
Mr. Clay Shorrock Esq. (Age 38)
J.D., Chief Legal Officer & Executive Director of Business Development
Mr. Tony Benson
Managing Director of EMEA
Mr. Joseph L. Magno
Sales Consultant
Mr. Warren Pearlson
Sales Consultant

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

APDN Stock Analysis - Frequently Asked Questions

Should I buy or sell Applied DNA Sciences stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Applied DNA Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" APDN shares.
View APDN analyst ratings or view top-rated stocks.
What is Applied DNA Sciences' stock price target for 2024?: 1 brokers have issued 12-month target prices for Applied DNA Sciences' stock. Their APDN share price targets range from $2.00 to $3.00. On average, they anticipate the company's share price to reach $2.50 in the next year. This suggests a possible upside of 183.8% from the stock's current price.
View analysts price targets for APDN or view top-rated stocks among Wall Street analysts.
How have APDN shares performed in 2023?: Applied DNA Sciences' stock was trading at $1.66 at the start of the year. Since then, APDN stock has decreased by 46.9% and is now trading at $0.8810.
View the best growth stocks for 2023 here.
When is Applied DNA Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our APDN earnings forecast.
How were Applied DNA Sciences' earnings last quarter?: Applied DNA Sciences, Inc. (NASDAQ:APDN) posted its quarterly earnings data on Thursday, December, 7th. The technology company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.01. The technology company had revenue of $0.78 million for the quarter, compared to analyst estimates of $1.60 million. Applied DNA Sciences had a negative net margin of 74.41% and a negative trailing twelve-month return on equity of 126.68%.

What is James A. Hayward's approval rating as Applied DNA Sciences' CEO?: 2 employees have rated Applied DNA Sciences Chief Executive Officer James A. Hayward on Glassdoor.com. James A. Hayward has an approval rating of 100% among the company's employees. This puts James A. Hayward in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Applied DNA Sciences to a friend.
What other stocks do shareholders of Applied DNA Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Applied DNA Sciences investors own include Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Ekso Bionics (EKSO), Micron Technology (MU), Arbutus Biopharma (ABUS), VBI Vaccines (VBIV), Gilead Sciences (GILD), Vaxart (VXRT), Sorrento Therapeutics (SRNE) and Intel (INTC).
Who are Applied DNA Sciences' major shareholders?: Applied DNA Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include AMH Equity Ltd (4.30%), Sabby Management LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends.
How do I buy shares of Applied DNA Sciences?: Shares of APDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:APDN) was last updated on 12/9/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial